Skip to main content

Baqsimi FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 6, 2020.

FDA Approved: Yes (First approved July 24, 2019)
Brand name: Baqsimi
Generic name: glucagon
Dosage form: Nasal Powder
Company: Eli Lilly and Company
Treatment for: Hypoglycemia

Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycemia in diabetes patients ages 4 years and older.

Development timeline for Baqsimi

Jul 24, 2019Approval FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.